For the Culture By The Culture
Cannabis rescheduling keeps resurfacing in headlines, then vanishing without action. This feature breaks down how federal officials repeatedly float reform language, let deadlines pass, and leave the law untouched. By tracing the mechanics behind the stall, the piece exposes why delay is intentional, who benefits from it, and why cannabis reform remains trapped in federal limbo.
The DEA is delaying the rescheduling of marijuana from Schedule I, despite overwhelming scientific support and recommendations from health authorities. This stalling harms the cannabis industry, patients, and communities affected by marijuana criminalization. Political influences from big pharmaceutical companies contribute to this resistance, prolonging the adverse effects of current drug policies.
